Olanzapine antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. A simple and reproducible RP-HPLC procedure was developed and validated as per ICH guidelines for the determination of related substances present in Olanzapine. After development of the method it was validated for specificity, system suitability, accuracy, linearity, precision, ruggedness and robustness. The value of theoretical plates, tailing factor, retention time and peak area was found to be within limits, hence it is concluded that the system is suitable to perform assay.
INTRODUCTION
Olanzapine antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia(1).Olanzapine binds to alpha(1), dopamine, histamine H1,muscarinic and serotonin type 2 (5-HT 2 ) receptors.Oral formulation: acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder.Intramuscular formulation: acute agitation associated with schizophrenia and bipolar I mania in adults(2,3).
Figure 1: Structure of Olanzapine

MATERIALS AND METHODS
Chemicals, Reagents and Samples
The chemicals, equipment and samples which were used in the present study was given in the following Tables.1-3 
Chromatographic conditions
The chromatographic conditions used in the present study were given in the following Table 4 . 
Stock solution-3
Weighed and transferred about each 10.0 mg of Related compound-C standard into 100 mL volumetric flask and dissolved in 20 mL of diluent and make upto mark with diluent.
Preparation of Identification solution
In the above stock solutions each 2.0mL of stock solution-1, stock solution-2 and stock olution-3 were transferred into a 50.0 mL volumetric flask and made up to mark with diluent. Further diluted from 1.0 mL to 10 mL with diluents.
Sample preparation
Weighed and transferred about 10.0 mg of sample into a 25 mL volumetric flask, dissolved in diluent and made up to the mark with diluent.
Procedure
The blank solution, standard solution, identification solution and sample solutions were injected and the retention times were recorded for the Olanzapine and Related compounds. 
RESULTS AND DISCUSSION System suitability
The system suitability & standard solution was prepared and analysed as per the proposed method for resolution between Related compound-A & Olanzapine peak in system suitability solution, the tailing factor for Olanzapine peak and the % RSD of four replicate injections in standard solution of Olanzapine peak to demonstrate system suitability for studying of each validation parameter(4,5). and a solution of all known specified impurities spiked with the Olanzapine at 1.0% level and finally Olanzapine sample was also prepared. All these solutions were analyzed by using the PDA detector(6). 
Accuracy
The accuracy was performed on samples spiked with known amounts of each specified impurity. The inherent amount of the individual impurity was taken into account.
The following concentrations were performed: 
Limit of detection (LOD)
The limit of detection (LOD) is defined as the lowest concentration of an analyte in a sample that can be detected, but not necessarily quantitated. The limit of detection was determined as the lowest concentration for which the response is approximately two times greater than the baseline noise (7). 
Limit of quantitation (LOQ)
The Limit of quantitation (LOQ) values was determined from the same experiment as mentioned in the limit of detection section. Based on the limit of detection, roughly three folds of limit of detection solution was prepared and analyzed for the determination of limit of quantitation(8). 
Linearity
The linearity of the HPLC method was demonstrated for Olanzapine and each specified impurity solutions ranging from LOQ to 250.0 % of the specification limit. Related compound-B 0.000025 mg/mL to 0.001010 mg/mL 6.25% to 252.5%
Related compound-A 0.000021 mg/mL to 0.001010 mg/mL 5.25% to 252.5%
Related compound-C 0.000045 mg/mL to 0.001000 mg/mL 11.25% to 250.0% Olanzapine 0.000111 mg/mL to 0.001010 mg/mL 27.75% to 252.5% CONCLUSION A simple and reproducible RP-HPLC procedure was developed and validated as per ICH guidelines for the determination of related substances present in Olanzapine. After development of the method it was validated for specificity, system suitability, accuracy, linearity, precision, ruggedness and robustness. The value of theoretical plates, tailing factor, retention time and peak area was found to be within limits, hence it is concluded that the system is suitable to perform assay. The method was found to be specific because it did not show any interference with standard and blank. The linearity studies were performed for the standard and found to be linear. It was evaluated by the visual inspection of the plot of peak area Vs concentration.
From the linearity studies, the specified range was found. The precision was checked and found to be within limits, hence the method is precise. The accuracy has been determined and % recovery was calculated and found to be within limits. The ruggedness of the method was checked on different systems and by different columns and standard was able to give same results which indicate that the method is rugged. The robustness of the method was checked by changing flow rate and temperature, and standard was able to give system suitability parameters within limit, which indicates that the method is robust. Therefore it was concluded that the proposed method can be used for routine analysis of determination of related substances present in Olanzapine. 
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